De Novo KRAS G12C–Mutant SCLC: A Case Report

Meridith L. Balbach,Rosana Eisenberg,Wade T. Iams

JTO Clinical and Research Reports（2022）

引用 1|浏览5

暂无评分

摘要

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

查看译文

关键词

KRAS G12C,Small cell lung cancer,Targeted therapy,Case report

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要